Proposed Project Work for the “SIB-SHInE Biodesign Program 2024”

Title: Development of a Chemokine Marker-Based Detection Kit for Early Diagnosis of

Breast Cancer

Principal Investigator:

Dr. Amaresh Mishra

Ph.D. in Cancer Biology, ICMR-Senior Research Fellow
School of Biotechnology, Gautam Buddha University, Greater Noida
Contact: amaresh.mishra007@gmail.com

1. Background: Breast cancer, a predominant cancer affecting women globally, necessitates

early detection for effective treatment and patient survival. Current methodologies, while
useful, are marred by high rates of misdiagnoses and false positives, underscoring an urgent
need for innovative solutions. My previous work on the CXCL12-CXCR4/CXCR7 axis in
breast cancer presents a novel avenue for the development of an enhanced detection kit.

2. Objective: The proposed project aims to develop, validate, and commercialize a novel
breast cancer detection kit based on chemokine markers, enhancing the accuracy, specificity,
and accessibility of early breast cancer diagnosis.

3. Methodology:

3.1. Research and Development:

 Identification of Biomarkers: Utilize bioinformatics tools to identify and validate

the most effective chemokine markers for breast cancer detection.
 Kit Development: Design and engineer a prototype detection kit targeting the
identified chemokine markers.

3.2. Validation:

 Conduct comprehensive in vitro and in vivo studies to validate the efficacy and
specificity of the detection kit.
  Collaborate with clinical partners for pilot testing and clinical validation in diverse
patient populations.

3.3. Commercialization Pathway:

 Develop a roadmap for regulatory approval, manufacturing, and market launch.

 Establish partnerships with biomedical companies and healthcare institutions for the
kit's distribution and use.

4. Expected Outcomes:

 A clinically validated breast cancer detection kit with higher specificity and accuracy.
 Enhanced early detection rates of breast cancer, leading to improved treatment
outcomes.
 Increased accessibility of breast cancer diagnostics, particularly in underserved
regions.

5. Significance: This project aligns with the urgent need for innovative medical technologies
in oncology, promising a significant impact on early breast cancer detection and treatment.
By improving diagnostic accuracy and reducing false positives, the project stands to
revolutionize breast cancer care, aligning with the SIB-SHInE program's mission to foster
healthcare innovation.

6. Timeline: The project is anticipated to be completed within 12 months, divided into

phases: six months for biomarker identification and kit development, six months for
validation studies, and if the extension is approved, the next six months for regulatory
approvals and initial production setup.

7. Conclusion: My expertise in cancer biology and chemokines, combined with the resources
and mentorship provided by the SIB-SHInE Biodesign program, presents a unique
opportunity to advance breast cancer diagnostics. This project not only contributes to
scientific and medical fields but also aligns with the program's goal of nurturing healthcare
innovations with global impact.